Pliant Therapeutics, Inc. financial data

Symbol
PLRX on Nasdaq
Location
331 Oyster Point Boulevard, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.19K % -16.6%
Debt-to-equity 34.3 % +80.2%
Return On Equity -71.5 % -46.2%
Return On Assets -53.3 % -29.6%
Operating Margin -78.4K % -5328%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.4M shares +0.98%
Common Stock, Shares, Outstanding 61.4M shares +0.99%
Entity Public Float 608M USD -39.7%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 61.4M shares +1.11%
Weighted Average Number of Shares Outstanding, Diluted 61.4M shares +1.11%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 132M USD -19.1%
General and Administrative Expense 53.8M USD -7.93%
Operating Income (Loss) -186M USD +16.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -175M USD +13%
Earnings Per Share, Basic -2 USD/shares +13.5%
Earnings Per Share, Diluted -2 USD/shares +13.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.7M USD +17.7%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 246M USD -40.1%
Property, Plant and Equipment, Net 4.34M USD -23.4%
Operating Lease, Right-of-Use Asset 24.8M USD -11.6%
Other Assets, Noncurrent 392K USD -8.2%
Assets 277M USD -37.9%
Accounts Payable, Current 485K USD -93%
Employee-related Liabilities, Current 6.95M USD -17.5%
Accrued Liabilities, Current 8.17M USD -15.9%
Liabilities, Current 17.6M USD -55.9%
Operating Lease, Liability, Noncurrent 28.2M USD -5.11%
Liabilities 76.3M USD -23.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 34K USD -96%
Retained Earnings (Accumulated Deficit) -836M USD -26.6%
Stockholders' Equity Attributable to Parent 200M USD -42.1%
Liabilities and Equity 277M USD -37.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -48.9M USD -61.4%
Net Cash Provided by (Used in) Financing Activities 498K USD -97.7%
Net Cash Provided by (Used in) Investing Activities 69.1M USD +16.1%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 61.4M shares +0.99%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 20.7M USD -59.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 95.2M USD +17.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 723K USD +44.3%
Deferred Tax Assets, Valuation Allowance 198M USD +28.9%
Deferred Tax Assets, Gross 205M USD +32%
Operating Lease, Liability 29.4M USD
Depreciation 1.76M USD -16.3%
Payments to Acquire Property, Plant, and Equipment 262K USD -82.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -176M USD +11.4%
Lessee, Operating Lease, Liability, to be Paid 39.3M USD -8.01%
Property, Plant and Equipment, Gross 16.4M USD +2.24%
Operating Lease, Liability, Current 1.19M USD +269%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.9M USD +33.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.41M USD +24.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.83M USD -21.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.47M USD +26.6%
Deferred Tax Assets, Operating Loss Carryforwards 94.9M USD +20.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.2M USD +28.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.47M USD
Operating Lease, Payments 800K USD +33.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 30.1M USD -21.5%
Interest Expense 1.4M USD +27.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%